StockData
Surrozen, Inc./DE logo

Surrozen, Inc./DE (SRZN) stock

SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30
$30.67−1.07 (-3.37%)

Close on Nov 19, 2026Market cap $360.48MP/E –Yield –

Surrozen shares outstanding

Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.

Surrozen's shares outstanding was 23M at Jun 30, 2026. For fiscal 2025 it was 0M, up 155.0% from the year before. The highest annual figure on record is 1M in fiscal 2020.

Annual shares outstanding

PeriodPeriod endValueChange
FY2025Dec 31, 20250M+155.0%
FY2024Dec 31, 20240M+45.3%
FY2023Dec 31, 20230M-12.8%
FY2022Dec 31, 20220M+40.6%
FY2021Dec 31, 20210M-99.8%
FY2020Dec 31, 20201M–

Quarterly shares outstanding

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 202623M+171.0%
Q1 FY2026Mar 31, 20260M+201.8%
Q4 FY2025Dec 31, 20250M+180.2%
Q3 FY2025Sep 30, 20250M+165.5%
Q2 FY2025Jun 30, 20259M+320.1%
Q1 FY2025Mar 31, 20250M-99.8%
Q4 FY2024Dec 31, 20240M+62.9%
Q3 FY2024Sep 30, 20240M+41.8%
Q3 FY2023Sep 30, 20232M-12.8%
Q2 FY2023Jun 30, 20232M-14.0%
Q1 FY2023Mar 31, 20230M-99.9%
Q4 FY2022Dec 31, 20220M-99.9%
Q3 FY2022Sep 30, 20222M+92.0%
Q2 FY2022Jun 30, 20222M+192434.5%
Q1 FY2022Mar 31, 20222M+92.6%
Q3 FY2021Sep 30, 20212M+48.1%
Q2 FY2021Jun 30, 20211M–
Q1 FY2021Mar 31, 20210M–
Q4 FY2020Dec 31, 20201M–
Q3 FY2020Sep 30, 20201M–

More Surrozen figures

See a number that looks wrong?